Posted by Michael Wonder on 06 Jun 2024
Neurogene announces NGN-401 gene therapy for Rett syndrome selected by FDA for START pilot program
3 June 2024 - NGN-401 is one of only three CBER programs chosen by FDA.
Neurogene today announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the US FDA Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.
